

Diabetic Macular Edema (Metabolic Disorder) - Drugs in Development, 2021

<https://marketpublishers.com/r/D2542EDC2A2FEN.html>

Date: March 2021

Pages: 375

Price: US\$ 2,500.00 (Single User License)

ID: D2542EDC2A2FEN

Abstracts

Diabetic Macular Edema (Metabolic Disorder) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema - Drugs in Development, 2021, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape.

Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Macular Edema - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development

by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 11, 21, 21, 2, 48 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Diabetic Macular Edema (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of

administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Diabetic Macular Edema - Overview

Diabetic Macular Edema - Therapeutics Development

Diabetic Macular Edema - Therapeutics Assessment

Diabetic Macular Edema - Companies Involved in Therapeutics Development

Diabetic Macular Edema - Drug Profiles

Diabetic Macular Edema - Dormant Projects

Diabetic Macular Edema - Discontinued Products

Diabetic Macular Edema - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Diabetic Macular Edema, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Companies, 2021 (Contd..2)
Number of Products under Development by Companies, 2021 (Contd..3)
Number of Products under Development by Companies, 2021 (Contd..4)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Companies, 2021 (Contd..5)
Products under Development by Companies, 2021 (Contd..6)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Target, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Diabetic Macular Edema - Pipeline by 3SBio Inc, 2021
Diabetic Macular Edema - Pipeline by 4D Molecular Therapeutics Inc, 2021
Diabetic Macular Edema - Pipeline by AbbVie Inc, 2021
Diabetic Macular Edema - Pipeline by Abpro Corp, 2021
Diabetic Macular Edema - Pipeline by Aciont Inc, 2021
Diabetic Macular Edema - Pipeline by Adverum Biotechnologies Inc, 2021
Diabetic Macular Edema - Pipeline by Aerie Pharmaceuticals Inc, 2021
Diabetic Macular Edema - Pipeline by Aerpio Pharmaceuticals Inc, 2021
Diabetic Macular Edema - Pipeline by Aldeyra Therapeutics Inc, 2021
Diabetic Macular Edema - Pipeline by Allegro Ophthalmics LLC, 2021
Diabetic Macular Edema - Pipeline by Allgenis Biotherapeutics Inc, 2021
Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals Inc, 2021
Diabetic Macular Edema - Pipeline by Apexian Pharmaceuticals Inc, 2021
Diabetic Macular Edema - Pipeline by Araim Pharmaceuticals Inc, 2021

Diabetic Macular Edema - Pipeline by Ascentage Pharma Group International, 2021
Diabetic Macular Edema - Pipeline by AsclepiX Therapeutics Inc, 2021
Diabetic Macular Edema - Pipeline by Ashvattha Therapeutics LLC, 2021
Diabetic Macular Edema - Pipeline by BetaStem Therapeutics Inc, 2021
Diabetic Macular Edema - Pipeline by Bio-Thera Solutions Ltd, 2021
Diabetic Macular Edema - Pipeline by Cell Care Therapeutics Inc, 2021
Diabetic Macular Edema - Pipeline by Celltrion Inc, 2021
Diabetic Macular Edema - Pipeline by Celon Pharma SA, 2021
Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, 2021
Diabetic Macular Edema - Pipeline by Chiome Bioscience Inc, 2021
Diabetic Macular Edema - Pipeline by Clearside BioMedical Inc, 2021
Diabetic Macular Edema - Pipeline by Curacle Co Ltd, 2021
Diabetic Macular Edema - Pipeline by Drive Therapeutics LLC, 2021
Diabetic Macular Edema - Pipeline by Elasmogen Ltd, 2021
Diabetic Macular Edema - Pipeline by Everglades Biopharma LLC, 2021
Diabetic Macular Edema - Pipeline by Exonate Ltd, 2021
Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals Inc, 2021
Diabetic Macular Edema - Pipeline by EyeGene Inc, 2021
Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, 2021
Diabetic Macular Edema - Pipeline by Gene Signal International SA, 2021
Diabetic Macular Edema - Pipeline by GlaxoSmithKline Plc, 2021
Diabetic Macular Edema - Pipeline by Graybug Vision Inc, 2021
Diabetic Macular Edema - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, 2021
Diabetic Macular Edema - Pipeline by Ikarovec Ltd, 2021
Diabetic Macular Edema - Pipeline by Isarna Therapeutics GmbH, 2021
Diabetic Macular Edema - Pipeline by Kalos Therapeutics Inc, 2021
Diabetic Macular Edema - Pipeline by Kalvista Pharmaceuticals Inc, 2021
Diabetic Macular Edema - Pipeline by Kanaph Therapeutics Inc, 2021
Diabetic Macular Edema - Pipeline by Kodiak Sciences Inc, 2021
Diabetic Macular Edema - Pipeline by Kowa Co Ltd, 2021
Diabetic Macular Edema - Pipeline by Kubota Vision Inc, 2021
Diabetic Macular Edema - Pipeline by Kur Therapeutics Ltd, 2021
Diabetic Macular Edema - Pipeline by Lupin Ltd, 2021
Diabetic Macular Edema - Pipeline by Luye Pharma Group Ltd, 2021
Diabetic Macular Edema - Pipeline by Mabion SA, 2021
Diabetic Macular Edema - Pipeline by Mabwell Shanghai Bioscience Co Ltd, 2021
Diabetic Macular Edema - Pipeline by Momenta Pharmaceuticals Inc, 2021

Diabetic Macular Edema - Pipeline by NeuMedics Inc, 2021
Diabetic Macular Edema - Pipeline by Novartis AG, 2021
Diabetic Macular Edema - Pipeline by Novelty Nobility Inc, 2021
Diabetic Macular Edema - Pipeline by Noveome Biotherapeutics Inc, 2021
Diabetic Macular Edema - Pipeline by OccuRx Pty Ltd, 2021
Diabetic Macular Edema - Pipeline by Ocugen Inc, 2021
Diabetic Macular Edema - Pipeline by Ocular Therapeutix Inc, 2021
Diabetic Macular Edema - Pipeline by Oculis SA, 2021
Diabetic Macular Edema - Pipeline by OcuNexus Therapeutics Inc, 2021
Diabetic Macular Edema - Pipeline by OcuTerra Therapeutics Inc, 2021
Diabetic Macular Edema - Pipeline by Opthea Ltd, 2021
Diabetic Macular Edema - Pipeline by Outlook Therapeutics Inc, 2021
Diabetic Macular Edema - Pipeline by Oxular Ltd, 2021
Diabetic Macular Edema - Pipeline by Oxurion NV, 2021
Diabetic Macular Edema - Pipeline by Pfizer Inc, 2021
Diabetic Macular Edema - Pipeline by Phanes Therapeutics Inc, 2021
Diabetic Macular Edema - Pipeline by PharmAbcine Inc, 2021
Diabetic Macular Edema - Pipeline by Pleryon Therapeutics Ltd, 2021
Diabetic Macular Edema - Pipeline by Profarma, 2021
Diabetic Macular Edema - Pipeline by Qilu Pharmaceutical Co Ltd, 2021
Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals Inc, 2021
Diabetic Macular Edema - Pipeline by RemeGen Co Ltd, 2021
Diabetic Macular Edema - Pipeline by Rezolute Inc, 2021
Diabetic Macular Edema - Pipeline by RiniSight Inc, 2021
Diabetic Macular Edema - Pipeline by Ripple therapeutics Corp, 2021
Diabetic Macular Edema - Pipeline by Semathera Inc, 2021
Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co Ltd, 2021
Diabetic Macular Edema - Pipeline by Suzhou Stainwei Biotech Inc, 2021
Diabetic Macular Edema - Pipeline by Targeted Therapy Technologies LLC, 2021
Diabetic Macular Edema - Pipeline by Uni-Bio Science Group Ltd, 2021
Diabetic Macular Edema - Pipeline by Unity Biotechnology Inc, 2021
Diabetic Macular Edema - Pipeline by Verseon Corp, 2021
Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, 2021
Diabetic Macular Edema - Pipeline by YD Life Science Co, 2021
Diabetic Macular Edema - Dormant Projects, 2021
Diabetic Macular Edema - Dormant Projects, 2021 (Contd..1)
Diabetic Macular Edema - Dormant Projects, 2021 (Contd..2)
Diabetic Macular Edema - Dormant Projects, 2021 (Contd..3)
Diabetic Macular Edema - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Diabetic Macular Edema, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

I would like to order

Product name: Diabetic Macular Edema (Metabolic Disorder) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/D2542EDC2A2FEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D2542EDC2A2FEN.html>